Enliven Therapeutics, Inc. (ELVN) Misses Q1 EPS by 23c

Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported Q1 EPS of ($0.80), $0.23 worse than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Enliven Therapeutics, Inc. (ELVN) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13
• The LGL Group (LGL) Misses Q2 EPS by 8c